Introduction
Cystic fibrosis (CF) is an autosomal recessive disorder and the most common fatal genetic disease affecting North Americans. 1, 2 The underlying cause of CF results from loss-of-function mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator protein (CFTR). [3] [4] [5] Wild-type CFTR is a phosphorylation dependent nucleotide regulated ion channel primarily responsible for the flux of chloride and bicarbonate across the apical membranes of epithelial tissues. 6 For individuals with CF, loss of CFTR activity results in dysregulation of ion flux and extracellular fluid composition. 7 CF affects including secondary targets for the compound of interest. 11 A variety of reporter tags can be utilized; such as radiolabels, fluorophores, biotin; or a latent group (such as an acetylene) that can be reacted with a tagging molecule via click chemistry following the photolabelling event. In recent years the diazirine has become a favoured choice of photoreactive group as it is stable to a wide range of reaction conditions, activated by a wavelength of light which does not significantly affect proteins or DNA (365 nm) and produces a very reactive singlet carbene which has a short half-life and can insert into N-H, C-H, and O-H bonds. 16, 17 Towards the goal of elucidating the binding site of 1 on mutant CFTR, we have synthesized PAL probe 2, featuring a diazirine moiety, based on the ivacaftor scaffold. Herein, we discuss the design and synthesis of 2, as well as initial characterization of its stability, photoreactivity, and functional activity on the CFTR channel. We have demonstrated the ability of 2 to efficiently label human serum albumin (HSA), a protein that has been previously reported to have a strong affinity for 1. 
Results and discussion

Retrosynthetic analysis
In generating PAL probe 2, it was important to ensure that the installation of the photoreactive group would not significantly alter the binding affinity and bioactivity compared to ivacaftor. It has been shown that modifications to either of the two t-butyl groups on the scaffold could be tolerated with retention of CFTR potentiating activity. 10 Modification of the t-butyl group ortho to the phenolic moiety affected the potentiation EC50 to a greater degree than did changes to the para-t-butyl, suggesting that the ortho group might have a closer interaction with the surface of the binding site on CFTR. 10 Considering the similar size and lipophilicity of a diazirine moiety compared to a t-butyl group, we envisaged a target PAL probe where a diazirine motif replaces the t-butyl group ortho to the phenolic moiety, and thus the molecule 2 was chosen as our target PAL probe.
Retrosynthetic analysis of compound 2 suggested two possible synthetic routes (Figure 1 ). The first involved forming an amide bond between carboxylic acid A (potentially substituted with a reporter tag), and an aniline B containing the diazirine moiety. B could be prepared from D where the diazirine group would be installed via manipulation of a synthetic handle such as X = Br or I. The second route reversed this process, forming the amide bond between aniline D and acid A to give compound C, followed by installation of the diazirine group (Figure 1 ).
Figure 1.
Retrosynthetic analysis of routes of synthesis of the diazirine-containing PAL probe (R indicates potential attachment of a reporter tag)
Synthesis of PAL probe 2
Initial synthetic efforts focused on the first route and synthesis of B (compound 3). The synthesis of 3 (Scheme 1) began from known phenol 4 with the reaction with chloromethyl ethyl ether to give 5. 19 Selective reduction of the nitro group in 5 proceeded smoothly with iron and ammonium chloride to give aniline 6, and subsequent protection of the aniline with di-t-butyl dicarbonate (Boc2O) gave 7. Installation of the trifluoromethyl ketone was achieved by first deprotonation of the amide NH with MeLi, followed by lithium-halogen exchange using n-BuLi, and quenching the resulting di-anion with ethyl trifluoroacetate to provide trifluoromethyl ketone 8 in excellent yield (95%). Compound 8 was reacted with hydroxylamine hydrochloride in a 2:1 pyridine/methanol mixture to give a mixture of E,Z isomers of oxime 9 in a 2:1 ratio (stereochemistry undetermined). Reaction of oximes 9 with p-toluenesulphonyl chloride gave tosyl-oximes 10 which were subsequently treated with liquid ammonia in a sealed vessel to give diaziridine 11. Upon close inspection, the crude reaction mixture was found to be a 2.7:1 mixture of an amidine by-product 12 and the desired diaziridine 11. Separation of 12 and isolation of pure 11 could be performed at this stage by either semi-preparative HPLC or selective crystallization, but this was somewhat demanding and low yielding. The identity of this side product 12 was unambiguously confirmed by single crystal X-ray diffraction (Scheme 1, Supplementary Information Figure S1 ). A better overall yield of the final product (the diazirine 13) and easier separation was achieved by carrying the mixture of 11 and 12 into the next step. Oxidation of the mixture of 11 and 12 with iodine and trimethylamine in methanol smoothly gave 13
(along with unchanged amidine 12), which was easily obtained pure via silica chromatography (shielded from light). The deprotection of 13 with methanolic hydrogen chloride produced the desired aniline 3;
however, this species was found to be very reactive with a short half-life, quickly forming adducts with solvent. Nonetheless, with 3 in hand, amide coupling reactions with 4-oxo-1,4-dihydroquinoline-3-carboxylic acid (14) were attempted under a variety of conditions, but all attempts resulted in loss of the diazirine and production of products of decomposition of the diazirine. Unfortunately, despite extreme precautions to exclude light, the aniline 3 proved to be too unstable to survive the relatively slow amide bond forming reactions with 14 and thus this approach was abandoned. Although we were unable to couple 3 with 14 with retention of the diazirine, we wanted to confirm that the photolytic decomposition of the diazirine group in the protected precursor 13 proceeded as expected. Thus, a solution of diazirine 13 in methanol was irradiated with UV light (365 nm) and the methanol photoadduct 15 was isolated in excellent yield (Scheme 2). Notably, while 3 was very unstable, 13 was found to be much less sensitive to light and we therefore surmised that installation of the diazirine after amide formation would have a greater chance of success.
Scheme 2. Photoreaction of diazirine 13 with MeOH
We therefore turned our attention to the alternative synthetic route (Figure 1 , path B) where the two halves of the molecule were coupled at an early stage and the diazirine installed later as shown in Scheme 3.
Coupling of aniline 6 and acid 14 with HATU gave bromo-amide 16 in good yield on multi-gram scale.
Lithium-halogen exchange of the bromine atom in 16 was achieved by first addition of 2 equiv of MeLi to remove the NH protons followed by treatment with n-BuLi to generate a tri-anion species, which upon reaction with ethyl trifluoroacetate produced trifluoromethyl ketone 17. Trifluoromethyl ketone 17 was isolated as a mixture of ketone and hydrate or hemi-ketal forms. At this stage, pure ketone 17 could be isolated by preparative-scale high-pressure liquid chromatography (prep-HPLC) in the absence of alcoholic solvents but only in low yields. However, carrying the original mixture forward directly into reaction with hydroxylamine hydrochloride gave the oximes 18 in better overall yield. In this way 18 could be isolated in 53% yield for the two steps as a mixture of E/Z isomers (2:1 ratio, undefined) by precipitation from DCM and without need for chromatography. Conversion of oximes 18 to the corresponding tosylate and formation of diaziridine 19 was carried out as a two-step, one-pot procedure.
After reaction of 18 with p-toluenesulphonyl chloride in DCM, the reaction mixture was transferred to a reaction vessel containing condensed liquid ammonia and sealed at - A solution of diazirine 2 in methanol was irradiated with UV light (365 nm) (Scheme 4) and monitored by HPLC and LC-MS which after 3 hours showed essentially complete conversion to the methanol adduct 22. Table S2 ) we could calculate the percentage labelling ( Figure 2 ) using the general formula:
% labelling = ________Peak A + Peak B X 100% Peak A + Peak B + Peak C + Peak D the extent of labelled protein was determined to be 37% (Figure 2 and Supplemental Information).
Examination of the extracted ion count (EIC) after 30 min of irradiation showed a significant amount of unreacted 2 remaining (data not shown). In order to ensure that labelling was via a UV-mediated process, a 1:1 solution of HSA and probe 2 was kept in the dark and monitored by LC-MS and showed a background labelling rate of 7% after 30 min, which is significantly lower than that obtained with overt UV exposure.
Competitive inhibition of the labelling of HSA by 2 with ivacaftor was evaluated to determine if the labelling events occurred in a manner specific for a putative ivacaftor binding site(s) on HSA. Addition of 150 µM ivacaftor to the solution of 1:1 mixture of 2 and HSA (both 1.5 µM in 3% DMSO in water) significantly reduced the extent of labelling by 2 (from 37% to 15%; p < 0.0001, Figure 2 ). No significant difference found in labelling after addition of 10 equiv (15 µM) of 1. However, significant inhibition of labelling was observed when ivacaftor (15 M) was first allowed to equilibrate with HSA for 30 minutes prior to addition of 2 and then irradiation ( Figure S3) . Photolabelling was not completely inhibited by ivacaftor under either condition indicating that at least some portion of the labelling of HSA by 2 was nonspecific which is not surprizing given the micromolar binding affinity of ivacaftor for HSA (vide supra) (and by inference also of 2) and the multiple potential binding sites available on HSA. ). B) Probe 2 (magenta) modelled, using Genetic Optimization for Ligand Docking (GOLD) version 5.5, in the multi-drug binding site on subdomain IIIA in a manner and orientation as described for ivacaftor by Schneider et al 18 .
In order to determine whether installation of the diazirine moiety onto the ivacaftor scaffold was deleterious to bioactivity, the ability of the probes to potentiate Wt-CFTR in HEK cells was determined using a FLIPR ® membrane potential assay, where changes in fluorescence are a readout of CFTR channel activity 25, 26 . A representative FLIPR ® trace is shown in Figure 4A . The response of the CFTR channel to activation by forskolin (leading to membrane depolarization) is enhanced by the addition of ivacaftor (1) or probe 2. As expected, the response to forskolin in the presence of both compounds was inhibited by the specific CFTR inhibitor: CFTRinh-172. 27 Analysis of the dose responses for each probe revealed that addition of the diazirine moiety shifted the EC50 for ivacaftor from 0.20 µM to 0.56 µM ( Figure 4B ) but did not significantly affect its efficacy. These results suggest that probe 2 is able to access the putative ivacaftor binding site on CFTR in a manner similar to 1. (1) and probe 2 (n=3-4). ΔFmax values were determined by subtracting ΔRFUFSK (changes in fluorescence from forskolin addition alone) from ΔRFUFSK+probe (changes in fluorescence from forskolin addition in the presence of varying concentrations of 1 or 2). From the fitted dose response curves, the EC50 values of 1 and 2 were determined to be 0.20 µM and 0.56 µM, respectively.
Conclusions
A photoaffinity labelling probe 2, based on the structure of ivacaftor and featuring a diazirine moiety in place of one of the t-butyl groups has been synthesized. The photoreactive properties of the diazirine moiety were confirmed by irradiating 2 in methanol at 365 nm to generate the methanol adduct 22. As well, photolabelling experiments with a model protein (HSA) have shown that 2 is able to label protein efficiently and in a specific manner that can be outcompeted by ivacaftor. Potent and comparable potentiation of ion channel activity of CFTR by 2 comparable to ivacaftor has been confirmed through the use of a fluorescence-based FLIPR assay with Wt-CFTR. This probe should be useful to identify the putative binding site(s) of ivacaftor on the CFTR ion channel.
Experimental
General Chemistry
THF was distilled from Na and benzophenone under N2. N,N'-diisopropylethylamine (DIPEA) and triethylamine (Et3N) were distilled from CaH2 and stored under N2. All other reagents and solvents were used as received from commercial suppliers unless otherwise stated. Analytical thin-layer chromatography (TLC) was performed on aluminum plates pre-coated with silica gel 60F-254 as the absorbent, and eluted with the solvent systems indicated, visualization of the plates was done with UV light (254 nm) and the indicated stains. Melting point was measured on a Fisher-Johns melting point apparatus and are uncorrected. Microwave reactions were conducted in a Biotage Initiator.
Flash chromatography was performed with a Biotage Isolera One system using SiliCycle SiliaSep TM Cartridges of indicated size and solvent gradient. For Single-Crystal X-ray diffraction structure determinations, single crystals were selected and mounted using Paratone oil on a 150 μm MiTeGen Dual-Thickness MicroMount. Data was collected at room temperature with a Bruker SMART APEX II Duo CCD diffractometer using a TRIUMPH graphite-monochromated Cu-Kα radiation (λ = 1.54184 Å). Crystallographic information for 12 can be found in Supplemental Information (Table S1, Figure S1 ). All diffraction data were processed with the Bruker Apex II software suite. Initial solutions were obtained by using the intrinsic phasing method 29 with subsequent refinements performed with SHELXL 30 on the SHELXLE platform. 31 Diagrams were prepared by using ORTEP-3 32 and POV-RAY. 33 
1-Bromo-5-(tert-butyl)-2-(ethoxymethoxy)-4-nitrobenzene (5)
To a solution of 2-bromo-4-(tert-butyl)-5-nitrophenol (4) (prepared according to DeMattei et al.) 19 (9.9 g, 36 mmol) in THF (60 mL) at room temperature under N2, DIPEA (19 mL, 109 mmol) was added, followed by chloromethyl ethyl ether (5.3 mL, 58 mmol) and stirred overnight. The reaction mixture was quenched with sat. aq. NH4Cl (100 mL), and extracted with Et2O (50 mL, 3x). The organic layers were combined, washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated to dryness to give compound 5 
4-Bromo-2-(tert-butyl)-5-(ethoxymethoxy)aniline (6)
To a solution of 1-bromo-5-(tert-butyl)-2-(ethoxymethoxy)-4-nitrobenzene (5) 
tert-Butyl (4-bromo-2-(tert-butyl)-5-(ethoxymethoxy)phenyl)carbamate (7)
A solution of aniline 6 (2. 
tert-butyl (2-(tert-butyl)-5-(ethoxymethoxy)-4-(2,2,2-trifluoro-1-((tosyloxy)imino)ethyl)phenyl)carbamate (10)
Et3N (170 μL, 1.22 mmol, 1.5 equiv) was added to a solution of 9 (353 mg, 0.81 mmol) in DCM (10 mL)
at 0 o C, via syringe and after stirring for 5 minutes, p-TsCl (170 mg, 0.89 mmol, 1.1 equiv.) was added and the reaction mixture was stirred for 15 minutes while warming to room temperature. The mixture was then quenched with sat. aq. NH4Cl (3 mL), washed with brine (3 mL), and dried (Na2SO4) to give tosyl oxime 10 as a crude yellow oil (495 mg) which was used directly in the subsequent step. 1 Alternatively, the reaction mixture could be used directly, before quenching and without workup, in the subsequent reaction to give diaziridine 11.
tert-butyl (2-(tert-butyl)-5-(ethoxymethoxy)-4-(3-(trifluoromethyl)diaziridin-3-yl)phenyl)carbamate (11) and tert-butyl (Z)-(4-((1-amino-2,2,2-trifluoroethylidene)amino)-2-(tert-butyl)-5-(ethoxymethoxy)phenyl)carbamate (12)
Ammonia was condensed (~1.5 mL) at -78 o C into a sealable reaction vessel, and a portion of the reaction mixture of tosyl-oxime 10 from above (theoretical mass of 118 mg, 0.2 mmol) in DCM (3 mL) was transferred via pipette into the liquid ammonia. The reaction vessel was sealed and the reaction mixture was warmed to room temperature in a water bath and stirred overnight. The reaction vessel was cooled at -78 o C for 15 minutes then carefully opened, and the reaction mixture was warmed at room temperature for 30 minutes. The reaction mixture was concentrated to dryness and the residue was purified by column chromatography on a 25 g silica cartridge (4-40 % EtOAc/Hex) to afford a mixture of diaziridine 11 and amidine 12 in a 1:2.7 ratio by 1 H NMR. The mixture of diaziridine 11 and amidine 12 can then be utilized directly in the next step (oxidation to diazirine 13) and separation of the diazirine 13 and amidine 12 postoxidation can be performed by automated flash chromatography.
For characterization purposes a mixture of 11 and 12 (80 mg, 1:2 ratio) was separated via preparative reverse phase HPLC to give 11 as a white crystalline solid (16 mg), and 12 as a white crystalline solid (20 mg). 12 was then recrystallized from an 8:2 Et2O/Hex mixture and the structure of 12 was confirmed by Xray crystallography (performed by CMH with instruction and assistance from JT). 
Characterization data for 11
tert-Butyl (2-(tert-butyl)-5-(ethoxymethoxy)-4-(3-(trifluoromethyl)-3H-diazirin-3-yl)phenyl)carbamate (13)
The mixture from above containing diaziridine 11 and amidine 12 (222 mg, 11:12 in ratio of 1:1.6, total 0.5 mmol) (calculated 11, 0.2 mmol) was dissolved in MeOH (3 mL) and Et3N (180 μl, 1.28 mmol, 2.5 equiv) was added and the reaction mixture was stirred for 5 minutes. I2 (71 mg, 0.56 mmol, 1.1 equiv) was added and the reaction mixture was stirred overnight and monitored by TLC. The reaction mixture was quenched with Na2S2O3 (aq.) and extracted into EtOAc (30 mL). The organic fractions were combined and washed with sat. aq. NaHCO3 (10 mL), brine (10 mL), dried over Na2SO4, and concentrated to dryness.
The crude residue was purified by automated flash chromatography on a 12 g silica cartridge (4-40% 
tert-Butyl (2-(tert-butyl)-5-(ethoxymethoxy)-4-(2,2,2-trifluoro-1-methoxyethyl)phenyl)carbamate (15)
A solution of diazirine 13 (3 mg, 7 μmol) dissolved in MeOH (300 μL) was placed in an NMR tube, which was suspended in a UV light-box comprised of two Dreamall UV lamps (described above) and irradiated for 48h. The reaction mixture was concentrated to dryness to give the methanol adduct 15 as a white solid 
5-Amino-4-(tert-butyl)-2-(3-(trifluoromethyl)-3H-diazirin-3-yl)phenol (3)
To a solution of compound 13 (62 mg, 0.144 mmol) dissolved in MeOH (1 mL 
N-(4-bromo-2-(tert-butyl)-5-(ethoxymethoxy)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (16)
A mixture of aniline 6 (2.00 g, 6.62 mmol), HATU (5.03 g, 6.62 mmol, 2 equiv), 1,4-dihydro-4-oxoquinoline-3-carboxylic acid (14) 
N-(2-(tert-butyl)-5-(ethoxymethoxy)-4-(2,2,2-trifluoroacetyl)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (17)
A solution of compound 16 (230 mg, 0.486 mmol) in THF (10 mL) under N2 was cooled at -40 o C and MeLi (1.6 M, 700 μL, 1.12 mmol, 2.3 equiv) was added via syringe and the reaction mixture was stirred for 2 min. At -40 o C, n-BuLi (1.58 M, 370 μL, 0.583 mmol, 1.5 equiv) was added dropwise via syringe and the reaction mixture was stirred a further 15 minutes. Ethyl trifluoroacetate (1.7 mL, 15 mmol, 30 equiv) was added quickly via syringe and the reaction mixture was warmed to 0 o C then quenched with saturated aqueous NH4Cl (1 mL). The reaction mixture was extracted into EtOAc (5 mL) and the organic fractions were combined and washed with brine (2 mL) dried over Na2SO4 and concentrated to dryness to give crude compound 17 as a yellow oil (270 mg). This crude material was utilized without purification in the subsequent oxime formation reaction.
For characterization purposes a portion of crude residue was purified by preparative reverse phase HPLC then lyophilized to give 17 ( 
N-(2-(tert-butyl)-5-(ethoxymethoxy)-4-(2,2,2-trifluoro-1-(hydroxyimino)ethyl)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (18)
Hydroxylamine hydrochloride (42 mg, 0.61 mmol, ~1. 
N-(2-(tert-butyl)-5-(ethoxymethoxy)-4-(3-(trifluoromethyl)diaziridin-3-yl)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (19) and (Z)-N-(4-((1-amino-2,2,2-trifluoroethylidene)amino)-2-(tert-butyl)-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (20)
DIPEA ( 
N-(2-(tert-butyl)-5-(ethoxymethoxy)-4-(3-(trifluoromethyl)-3H-diazirin-3-yl)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (21)
DMP (38 mg, 0.090 mmol, 3.0 equiv.) was added to a solution of diaziridine 19 (15 mg, 0.030 mmol) in DCM (300 μL) in an amber vial wrapped in foil and the reaction mixture was stirred for 1 hour. The reaction mixture was quenched with 1M aqueous NaOH (2 mL), and the organic layer was washed with H2O (2 mL), brine (1 mL) and dried over Na2SO4, filtered, and blown dry under a stream of N2 then dried under vacuum to give 21 (11 mg, 0.022 mmol, 74% yield) as a white powder (>95% pure by 
N-(2-(tert-butyl)-5-hydroxy-4-(3-(trifluoromethyl)-3H-diazirin-3-yl)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (2)
Saturated methanolic HCl (250 μL) was added to a solution of diazirine 21 (11 mg, 0.022 mmol) in MeOH 
N-(2-(tert-butyl)-5-hydroxy-4-(2,2,2-trifluoro-1-methoxyethyl)phenyl)-4-oxo-1,4-dihydroquinoline-
3-carboxamide (22)
A solution of diazirine 2 (7 mg, 0.016 mmol) in MeOH (1 mL), in a clear vial was placed on its side onto an upturned UVP Mineralight © lamp (115 V, 60 Hz, 0.16 A) and irradiated at 365 nm (long UV wavelength setting). The progress of the reaction was monitored by HPLC and LC-MS. After 3 hours of irradiation the majority of the starting material was converted to a new species with mass corresponding to the methanol adduct, the reaction mixture was then blown dry under nitrogen. A pure sample of 22 was obtained by silica chromatography (75-100 % EtOAc/Hex); compound 22 (1 mg). 
FLiPR membrane potential assay:
The FLiPR membrane potential assay was conducted as previously described by Molinski et al. 34 HEK cells expressing Wt-CFTR were grown in black 96 well Costar plates with clear bottoms at 37°C with 5% CO2. When the cells reached 100% confluency, they were loaded with blue membrane potential dye (Molecular Probes TM ) at 0.5 mg/mL dissolved in a buffer containing 136 mM sodium gluconate, 3 mM potassium gluconate, 10 mM glucose and 20 mM HEPES (pH 7.35, 300mOsm). After a 45 minute incubation time at 37 °C, the plate fluorescence was read with a SpectraMax i3x plate reader (Molecular Devices) with the excitation and emission wavelengths set at 530nm and 560nm, respectively.
The baseline was first read for five minutes. Forskolin (Sigma), VX-770 or its analog were added subsequently to stimulate CFTR channel activity for 10 minutes; CFTR inhibitor 172 (Cystic Fibrosis Foundation Therapeutics) was added at the end of the assay to inhibit CFTR channel activity for 10 minutes.
Statistical analysis was performed using GraphPad Prism v6.01.
Photolabelling of HSA:
Lyophilized recombinant human serum albumin (HSA) (Lot # SLBN1719V) was purchased from Sigma- Deconvolution of the TIC signal was performed in MassHunter TM to obtain the mass spectrum for HSA.
The peak lists for each HSA mass spectrum time point were exported to a spreadsheet (Supplemental Information Table S2 ). The percent labelling value was calculated from the ratio of peak abundances of the major labelled and unlabelled HSA peaks at t = 30 min using the following formula (Section 2. 
Mass Spectrometry analysis of HSA peptide fragments:
The purified peptides were dissolved in 40 µL of 0.1% formic acid and analyzed on a Q Exactive HF scans is of 1E6 and 1E3, respectively. Precursors with changes of >5, and the unassigned were excluded from MS2 scans.
MS/MS data analysis:
The resolved raw files from Q-Exactive HF ® were processed by Proteome Discoverer 2.1 ® (Thermo Scientific, Mississauga, ON, Canada) and searched using Sequest HT ® . The acquired spectra were searched against a customized database, combining target HSA sequence with the yeast Uniprot database and common contaminants. 35 The monoisotopic precursor mass tolerance was 10 ppm, and the monoisotopoic fragment mass tolerance was 0.02Da. Criteria of a minimum of 6 amino acids and 2 miss cleavages were used for search. Cysteine carbamidomethylation (+57.05130) was treated as a fixed modification, and all the other amino acids were treated as the dynamic modification (+416.13478) by the insertion of carbene species generated from probe 2. The reversed sequences of the original searching 
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